Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials [Yahoo! Finance]
Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ:AMEX Investor Relations:
ir.citiuspharma.com
Company Research
Source: Yahoo! Finance
Shares Outstanding : As of December 31, 2023, there were 158,966,576 common shares outstanding. R&D Expenses : R&D expenses decreased to $2.6 million in Q1 2024 from $3.4 million in Q1 2023. G&A Expenses : G&A expenses increased to $3.7 million in Q1 2024 from $2.6 million in Q1 2023. Net Loss : Net loss widened to $9.2 million, or ($0.06) per share, in Q1 2024 compared to a net loss of $3.6 million, or ($0.02) per share, in Q1 2023. Stock-based Compensation : Stock-based compensation expense increased to $3.1 million in Q1 2024 from $1.2 million in Q1 2023. Warning! GuruFocus has detected 1 Warning Sign with CTXR. On February 14, 2024, Citius Pharmaceuticals Inc ( NASDAQ:CTXR ) released its 8-K filing , detailing its financial results for the fiscal first quarter of 2024 which ended on December 31, 2023. The company, a late-stage biopharmaceutical entity, is focused on developing and commercializing critical care products, including its four proprietary product candidate
Show less
Read more
Impact Snapshot
Event Time:
CTXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTXR alerts
High impacting Citius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CTXR
News
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingPR Newswire
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingPR Newswire
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma [Yahoo! Finance]Yahoo! Finance
CTXR
Earnings
- 2/14/24 - Miss
CTXR
Analyst Actions
- 2/14/24 - HC Wainwright
CTXR
Sec Filings
- 4/30/24 - Form 8-K
- 4/26/24 - Form 424B5
- 4/5/24 - Form 8-K
- CTXR's page on the SEC website